HIGHLIGHTS
SUMMARY
Both formulations showed a sustained drug release up to 24 h, maintaining the samethe trend, niosome formulations showed a sustained drug release up to 24 h, maintaining same reaching values of 55.4% doxorubicin release from NIO + DOXO and 85.7% from NIO-F + trend, reaching values of 55.4% doxorubicin release from NIO + DOXO and 85.7% from DOXO, respectively. CBA 1 inhibited breast cancer cell via3.5.Cell Cell Viability Assay viability was measured in MDA-MB-231 cells exposed for 72 h to CBA 1 or to bility with an IC50 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.